ExactAb™,低内毒素,已验证,无动物源,无叠氮钠,无载体,重组 级 提供 ≥90%(SDS-PAGE&SEC-HPLC) 纯度，适用于对基线干扰要求严格的色谱和分析工作流程。
-80℃储存,避免反复冻融。特低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Lifastuzumab vedotin (anti-SLC34A2) 是一种抗体药物偶联物 (ADC)，由人源化抗 NaPi2b 单克隆抗体和抗有丝分裂细胞毒剂单甲基 auristatin E (MMAE) 组成 。Lifastuzumab vedotin (anti-SLC34A2) 用于治疗铂耐药卵巢癌。
Lifastuzumab vedotin (anti-SLC34A2) is an antibody-drug conjugate (ADC) composed of a humanized anti-NaPi2b monoclonal antibody and an anti-mitotic cytotoxic agent, monomethyl auristatin E (MMAE) . Lifastuzumab vedotin (anti-SLC34A2) is used in the treatment of platinum-resistant ovarian cancer.
Purity
≥90% (SDS-PAGE&SEC)
Endotoxin Level
< 1.0EU/mg
Lifastuzumab vedotin (anti-SLC34A2) (Ab175578) - Flow Cytometry
Flow Cytometry analysis of SK-OV-3 cells labelling SLC34A2 (red) with Lifastuzumab vedotin (anti-SLC34A2) (Ab175578). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Lifastuzumab vedotin (anti-SLC34A2) (Ab175578) - ELISA
Immobilized Recombinant Human SLC34A2-NhFc protein at 2.0 μg/mL can bind Lifastuzumab vedotin (anti-SLC34A2) (Ab175578) with the EC
₅₀
of 61.75 ng/mL.
Lifastuzumab vedotin (anti-SLC34A2) (Ab175578) - SEC
The purity of Lifastuzumab vedotin (anti-SLC34A2) (Ab175578) is more than 95% verified by HPLC.
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
 ZJ24F0910012 |
分析证书 | Ab175578 |
| ZJ24F0910013 |
分析证书 | Ab175578 |
| ZJ24F0910014 |
分析证书 | Ab175578 |
我们的级别选择指南涵盖了目录中所有的变体的纯度、稳定剂状态和应用适用性。
查看 Animal Free 级别指南 → 查看 Carrier Free 级别指南 → 查看 Recombinant 级别指南 → 查看 Validated 级别指南 → 查看 ExactAb™ 级别指南 → 查看 Low Endotoxin 级别指南 → 查看 Azide Free 级别指南 →
危险品化学品经营许可证（带存储）